NCT00300118View on ClinicalTrials.gov

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

PHASE3CompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Crohn's Disease
Interventions
DRUG

budesonide

9 mg

DRUG

mesalazine

4.5 g

Trial Locations (1)

45525

Ev. Krankenhaus Hattingen GmbH, Hattingen

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY